Tauopathies: all 75 studies

Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• Tau Pathology in the Brain After Hip or Knee Replacement SurgeryRecruitingNCT07871487
• A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary TauopathiesNot yet recruitingNCT07868328Phase 2
• Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - EUNot yet recruitingNCT07708675Not applicable
• An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease PsychosisEnrolling by invitationNCT07459660Phase 2
• [18F]NIDF PET Imaging in Tau-related DiseasesRecruitingNCT07306598
• Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary TauopathiesRecruitingNCT07221344Phase 1/2
• Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183ARecruitingNCT06932809Early Phase 1
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRecruitingNCT06887192Phase 2
• Tau PET/CT in Various Tau-Related Disease PatientsRecruitingNCT06690983
• Neurodegenerative Diseases Progression Markers (MARKERS-NDD)RecruitingNCT06596746
• Proteinopathies Expression in Skin of Neurodegenerative DisordersRecruitingNCT06528964
• Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503RecruitingNCT06303921Early Phase 1
• A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseRecruitingNCT06297590Phase 1
• Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)RecruitingNCT06170268
• CW2IP2: Imaging and Diagnostic AssessmentsRecruitingNCT06083467Not applicable
• Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15RecruitingNCT06032026Early Phase 1
• Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute ConditionsRecruitingNCT04684602Phase 1/2
• F 18 T807 Tau PET Imaging of Alzheimer's DiseaseRecruitingNCT02414347
• A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationCompletedNCT05318976Phase 2Results posted
• Harmony at Home: A Pilot Telehealth Program for Rural ADRD CaregiversCompletedNCT05202223Not applicableResults posted
• Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care SystemsCompletedNCT05080777Not applicableResults posted
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseCompletedNCT05063539Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's DiseaseCompletedNCT04445831Phase 1/2Results posted
• A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's DiseaseCompletedNCT03765762Phase 2Results posted
• A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseCompletedNCT03518073Phase 2Results posted
• An Open-Label Crenezumab Study in Participants With Alzheimer's DiseaseTerminatedNCT03491150Phase 3Results posted
• An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)TerminatedNCT03391765Phase 2Results posted
• Nicotinamide as an Early Alzheimer's Disease TreatmentCompletedNCT03061474Phase 2Results posted
• A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)TerminatedNCT02985879Phase 2Results posted
• A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease DementiaTerminatedNCT02972658Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's DiseaseCompletedNCT02880956Phase 2Results posted
• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease DementiaTerminatedNCT02783573Phase 3Results posted
• Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT MutationsCompletedNCT02676843Phase 2Results posted
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's DiseaseTerminatedNCT02245737Phase 2/3Results posted
• A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type DementiaCompletedNCT01276353Phase 2Results posted
• First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the BrainCompletedNCT07348276Early Phase 1
• Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD SubjectsTerminatedNCT06304883Phase 3
• A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01TerminatedNCT06247345Phase 1
• A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)CompletedNCT05532358Phase 1
• A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese PopulationCompletedNCT05527288Not applicable
• An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseTerminatedNCT05522387Phase 2
• A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)Active, not recruitingNCT05508789Phase 3
• Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsActive, not recruitingNCT05469360Phase 1
• Validation of Blood Biomarkers for Alzheimer's DiseaseCompletedNCT05427448Not applicable
• Head-to-Head Harmonization of Tau Tracers in Alzheimer's DiseaseActive, not recruitingNCT05361382Phase 1
• A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy ParticipantsActive, not recruitingNCT05344989Phase 1
• Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationWithdrawnNCT05321498Phase 2
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's DiseaseCompletedNCT04685265Phase 1
• Myotonic Dystrophy - Vascular and CognitionActive, not recruitingNCT04656210
• Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear PalsyStatus unknownNCT04541836
• A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy SubjectsCompletedNCT04208152Phase 1
• CNS Tau Kinetics in Healthy Aging and Alzheimer's DiseaseCompletedNCT03938870
• Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's DiseaseCompletedNCT03903211Phase 2
• Expanded Access to ABBV-8E12No longer availableNCT03744546
• Human CNS Tau Kinetics in TauopathiesCompletedNCT03545126
• A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831CompletedNCT03538522Phase 2
• Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the BrainCompletedNCT03510572Early Phase 1
• Novel Neuroimage Study in Tauopathies With ParkinsonismCompletedNCT03386669Phase 2
• Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in HumansCompletedNCT03287765
• F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & UninfectedCompletedNCT03279523
• A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive AphasiaStatus unknownNCT03174886Phase 1
• Transcranial Magnetic Stimulation in Nonfluent/Agrammatic Variant Primary Progressive AphasiaTerminatedNCT03153540Not applicable
• COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICECompletedNCT02860338
• F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)WithdrawnNCT02707978Phase 2
• Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyCompletedNCT02494024Phase 1
• F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral SclerosisCompletedNCT02414230
• A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy SubjectsCompletedNCT02294851Phase 1
• Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain InjuryCompletedNCT02266563
• 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified ParkinsonismCompletedNCT02214862Early Phase 1
• Olfactory Neuroepithelial Tissue of Alzheimer DiseaseCompletedNCT02129452
• Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsCompletedNCT02103894Phase 1
• Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006TerminatedNCT02008513Phase 2
• The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-ADStatus unknownNCT01696591
• Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's DiseaseCompletedNCT01539031Phase 3
• A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's DiseaseCompletedNCT01404169Phase 3

← Tauopathies overview